vs
CENTRAL GARDEN & PET CO（CENT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是CENTRAL GARDEN & PET CO的1.3倍（$772.1M vs $617.4M），Revvity净利率更高（12.7% vs 1.1%，领先11.6%），Revvity同比增速更快（5.9% vs -6.0%），Revvity自由现金流更多（$161.8M vs $-81.0M），过去两年Revvity的营收复合增速更高（9.0% vs -17.2%）
Central Garden & Pet Co是总部位于美国的宠物用品及园艺产品供应商，主营宠物食品、护理用具、草坪养护用品、园艺配件等品类，产品通过大型商超、独立宠物店、园艺中心等渠道销往北美市场，旗下拥有多个行业知名消费品牌。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CENT vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$617.4M
营收增速更快
RVTY
高出11.8%
-6.0%
净利率更高
RVTY
高出11.6%
1.1%
自由现金流更多
RVTY
多$242.8M
$-81.0M
两年增速更快
RVTY
近两年复合增速
-17.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $617.4M | $772.1M |
| 净利润 | $6.8M | $98.4M |
| 毛利率 | 30.9% | — |
| 营业利润率 | 2.7% | 14.5% |
| 净利率 | 1.1% | 12.7% |
| 营收同比 | -6.0% | 5.9% |
| 净利润同比 | -51.2% | 3.9% |
| 每股收益（稀释后） | $0.11 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CENTRVTY
| Q4 25 | $617.4M | $772.1M | ||
| Q3 25 | $678.2M | $698.9M | ||
| Q2 25 | $960.9M | $720.3M | ||
| Q1 25 | $833.5M | $664.8M | ||
| Q4 24 | $656.4M | $729.4M | ||
| Q3 24 | $669.5M | $684.0M | ||
| Q2 24 | $996.3M | $691.7M | ||
| Q1 24 | $900.1M | $649.9M |
净利润CENTRVTY
| Q4 25 | $6.8M | $98.4M | ||
| Q3 25 | $-9.8M | $46.7M | ||
| Q2 25 | $95.0M | $53.9M | ||
| Q1 25 | $63.6M | $42.2M | ||
| Q4 24 | $14.0M | $94.6M | ||
| Q3 24 | $-34.2M | $94.4M | ||
| Q2 24 | $79.7M | $55.4M | ||
| Q1 24 | $62.0M | $26.0M |
毛利率CENTRVTY
| Q4 25 | 30.9% | — | ||
| Q3 25 | 29.0% | 53.6% | ||
| Q2 25 | 34.6% | 54.5% | ||
| Q1 25 | 32.8% | 56.5% | ||
| Q4 24 | 29.8% | — | ||
| Q3 24 | 25.2% | 56.3% | ||
| Q2 24 | 31.8% | 55.7% | ||
| Q1 24 | 31.0% | 54.6% |
营业利润率CENTRVTY
| Q4 25 | 2.7% | 14.5% | ||
| Q3 25 | -0.9% | 11.7% | ||
| Q2 25 | 14.1% | 12.6% | ||
| Q1 25 | 11.2% | 10.9% | ||
| Q4 24 | 4.3% | 16.3% | ||
| Q3 24 | -4.8% | 14.3% | ||
| Q2 24 | 11.6% | 12.4% | ||
| Q1 24 | 10.4% | 6.8% |
净利率CENTRVTY
| Q4 25 | 1.1% | 12.7% | ||
| Q3 25 | -1.4% | 6.7% | ||
| Q2 25 | 9.9% | 7.5% | ||
| Q1 25 | 7.6% | 6.4% | ||
| Q4 24 | 2.1% | 13.0% | ||
| Q3 24 | -5.1% | 13.8% | ||
| Q2 24 | 8.0% | 8.0% | ||
| Q1 24 | 6.9% | 4.0% |
每股收益（稀释后）CENTRVTY
| Q4 25 | $0.11 | $0.86 | ||
| Q3 25 | $-0.16 | $0.40 | ||
| Q2 25 | $1.52 | $0.46 | ||
| Q1 25 | $0.98 | $0.35 | ||
| Q4 24 | $0.21 | $0.77 | ||
| Q3 24 | $-0.51 | $0.77 | ||
| Q2 24 | $1.19 | $0.45 | ||
| Q1 24 | $0.93 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $721.1M | $919.9M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $1.6B | $7.3B |
| 总资产 | $3.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.76× | — |
8季度趋势，按日历期对齐
现金及短期投资CENTRVTY
| Q4 25 | $721.1M | $919.9M | ||
| Q3 25 | $882.5M | $931.4M | ||
| Q2 25 | $713.0M | $991.8M | ||
| Q1 25 | $516.7M | $1.1B | ||
| Q4 24 | $618.0M | $1.2B | ||
| Q3 24 | $753.5M | $1.2B | ||
| Q2 24 | $570.4M | $2.0B | ||
| Q1 24 | $301.3M | $1.7B |
总债务CENTRVTY
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
股东权益CENTRVTY
| Q4 25 | $1.6B | $7.3B | ||
| Q3 25 | $1.6B | $7.4B | ||
| Q2 25 | $1.6B | $7.6B | ||
| Q1 25 | $1.5B | $7.6B | ||
| Q4 24 | $1.5B | $7.7B | ||
| Q3 24 | $1.6B | $7.9B | ||
| Q2 24 | $1.6B | $7.9B | ||
| Q1 24 | $1.5B | $7.8B |
总资产CENTRVTY
| Q4 25 | $3.6B | $12.2B | ||
| Q3 25 | $3.6B | $12.1B | ||
| Q2 25 | $3.7B | $12.4B | ||
| Q1 25 | $3.6B | $12.4B | ||
| Q4 24 | $3.5B | $12.4B | ||
| Q3 24 | $3.6B | $12.8B | ||
| Q2 24 | $3.6B | $13.4B | ||
| Q1 24 | $3.5B | $13.4B |
负债/权益比CENTRVTY
| Q4 25 | 0.76× | — | ||
| Q3 25 | 0.75× | — | ||
| Q2 25 | 0.75× | — | ||
| Q1 25 | 0.77× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 0.79× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-70.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-81.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -13.1% | 21.0% |
| 资本支出强度资本支出/营收 | 1.8% | 2.6% |
| 现金转化率经营现金流/净利润 | -10.26× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $285.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CENTRVTY
| Q4 25 | $-70.2M | $182.0M | ||
| Q3 25 | $182.7M | $138.5M | ||
| Q2 25 | $265.5M | $134.3M | ||
| Q1 25 | $-46.9M | $128.2M | ||
| Q4 24 | $-68.8M | $174.2M | ||
| Q3 24 | $203.1M | $147.9M | ||
| Q2 24 | $286.1M | $158.6M | ||
| Q1 24 | $-24.5M | $147.6M |
自由现金流CENTRVTY
| Q4 25 | $-81.0M | $161.8M | ||
| Q3 25 | $171.9M | $120.0M | ||
| Q2 25 | $251.7M | $115.5M | ||
| Q1 25 | $-57.5M | $112.2M | ||
| Q4 24 | $-74.9M | $149.8M | ||
| Q3 24 | $193.0M | $125.6M | ||
| Q2 24 | $272.5M | $136.6M | ||
| Q1 24 | $-33.9M | $129.7M |
自由现金流率CENTRVTY
| Q4 25 | -13.1% | 21.0% | ||
| Q3 25 | 25.3% | 17.2% | ||
| Q2 25 | 26.2% | 16.0% | ||
| Q1 25 | -6.9% | 16.9% | ||
| Q4 24 | -11.4% | 20.5% | ||
| Q3 24 | 28.8% | 18.4% | ||
| Q2 24 | 27.3% | 19.7% | ||
| Q1 24 | -3.8% | 20.0% |
资本支出强度CENTRVTY
| Q4 25 | 1.8% | 2.6% | ||
| Q3 25 | 1.6% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 1.3% | 2.4% | ||
| Q4 24 | 0.9% | 3.4% | ||
| Q3 24 | 1.5% | 3.3% | ||
| Q2 24 | 1.4% | 3.2% | ||
| Q1 24 | 1.0% | 2.7% |
现金转化率CENTRVTY
| Q4 25 | -10.26× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 2.79× | 2.49× | ||
| Q1 25 | -0.74× | 3.03× | ||
| Q4 24 | -4.91× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 3.59× | 2.87× | ||
| Q1 24 | -0.40× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CENT
| Garden Products Segment | $201.6M | 33% |
| Dogand Cat Products | $157.0M | 25% |
| Other Pet Products | $117.8M | 19% |
| Manufactured Product Other | $102.5M | 17% |
| Wild Bird Products | $38.5M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
